Information

Related Research Units

Levin Lab Research

Research Background

Dr. April Levin's clinical work and research focus on management of autism from a child neurology perspective. In the neurology clinic, her focus is on caring for children with autism. In addition to seeing patients, she is working to implement an online parent questionnaire that will help families and clinicians monitor outcomes over time in children with autism. Her primary research focuses on identifying biomarkers of autism, using information about brain rhythms as measured by EEG. The long-term goal of this research is to find new ways to predict, diagnose, and monitor autism; in the process, she hopes to shed light on how the brain works in children with autism. She is also involved with the Bucharest Early Intervention Project, which examines the effects of institutionalization versus foster care on child development. Alongside her participation in this research project, she has been involved in clinical, teaching, and volunteer work in Romanian hospitals and orphanages since 1999.

Education

Undergraduate School

Brown University
2003 Providence RI

Medical School

Yale University School of Medicine
2007 New Haven CT

Residency

Boston Combined Residency Program (BCRP)
2009 Boston MA

Residency

Neurology Boston Children's Hospital
2012 Boston MA

Fellowship

Behavioral Neurology Boston Children's Hospital
2014 Boston MA

Fellowship

Postdoctoral Research Boston Children's Hospital
2014 Boston MA

Publications

  1. Associations Among EEG Aperiodic Slope, Infant Temperament, and Maternal Anxiety/Depression Symptoms in Infancy. Psychophysiology. 2025 Jan; 62(1):e14757. View Abstract
  2. A roadmap for SHANK3-related Epilepsy Research: recommendations from the 2023 strategic planning workshop. Ther Adv Rare Dis. 2024 Jan-Dec; 5:26330040241273464. View Abstract
  3. Early differential impact of MeCP2 mutations on functional networks in Rett syndrome patient-derived human cerebral organoids. bioRxiv. 2024 Aug 10. View Abstract
  4. Parsing evoked and induced gamma response differences in Autism: A visual evoked potential study. Clin Neurophysiol. 2024 Sep; 165:55-63. View Abstract
  5. Modeling intra-individual inter-trial EEG response variability in autism. Stat Med. 2024 Jul 30; 43(17):3239-3263. View Abstract
  6. Constrained Multivariate Functional Principal Components Analysis for Novel Outcomes in Eye-Tracking Experiments. Stat Biosci. 2024 Dec; 16(3):578-603. View Abstract
  7. Clinically derived 12-factor structure and confirmatory factor analysis of the neurodevelopmental parent report for outcome monitoring. Front Psychiatry. 2023; 14:1243467. View Abstract
  8. Evaluation of clinical assessments of social abilities for use in autism clinical trials by the autism biomarkers consortium for clinical trials. Autism Res. 2023 05; 16(5):981-996. View Abstract
  9. A circuit-level biomarker of Rett syndrome based on ectopic phase-amplitude coupling during slow-wave-sleep. Cereb Cortex. 2023 03 10; 33(6):2559-2572. View Abstract
  10. Associations Between Infant Screen Use, Electroencephalography Markers, and Cognitive Outcomes. JAMA Pediatr. 2023 03 01; 177(3):311-318. View Abstract
  11. The role of aperiodic spectral slope in event-related potentials and cognition among children with and without attention deficit hyperactivity disorder. J Neurophysiol. 2022 12 01; 128(6):1546-1554. View Abstract
  12. A randomized controlled trial of everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome. Hum Mol Genet. 2022 10 10; 31(20):3393-3404. View Abstract
  13. Concomitant medication use in children with autism spectrum disorder: Data from the Autism Biomarkers Consortium for Clinical Trials. Autism. 2023 05; 27(4):952-966. View Abstract
  14. A functional model for studying common trends across trial time in eye tracking experiments. Stat Biosci. 2023 Apr; 15(1):261-287. View Abstract
  15. The Autism Biomarkers Consortium for Clinical Trials: Initial Evaluation of a Battery of Candidate EEG Biomarkers. Am J Psychiatry. 2023 01 01; 180(1):41-49. View Abstract
  16. Absence of dynamic neural oscillatory response to environmental conditions marks childhood attention deficit hyperactivity disorder. J Child Psychol Psychiatry. 2022 12; 63(12):1615-1621. View Abstract
  17. Multilevel hybrid principal components analysis for region-referenced functional electroencephalography data. Stat Med. 2022 08 30; 41(19):3737-3757. View Abstract
  18. Identifying Age Based Maturation in the ERP Response to Faces in Children With Autism: Implications for Developing Biomarkers for Use in Clinical Trials. Front Psychiatry. 2022; 13:841236. View Abstract
  19. The autism biomarkers consortium for clinical trials: evaluation of a battery of candidate eye-tracking biomarkers for use in autism clinical trials. Mol Autism. 2022 03 21; 13(1):15. View Abstract
  20. Bridges Through the Cloud: Towards Clinical Biomarkers of Cognitive Neurophysiology. J Clin Neurophysiol. 2022 02 01; 39(2):99-100. View Abstract
  21. Neurobehavioral Biomarkers: An EEG Family Reunion. J Clin Neurophysiol. 2022 Feb 01; 39(2):129-134. View Abstract
  22. Parental Language Input Predicts Neuroscillatory Patterns Associated with Language Development in Toddlers at Risk of Autism. J Autism Dev Disord. 2022 Jun; 52(6):2717-2731. View Abstract
  23. EEG Phase-Amplitude Coupling Strength and Phase Preference: Association with Age over the First Three Years after Birth. eNeuro. 2021 May-Jun; 8(3). View Abstract
  24. Shifted phase of EEG cross-frequency coupling in individuals with Phelan-McDermid syndrome. Mol Autism. 2021 04 28; 12(1):29. View Abstract
  25. Autism Spectrum Disorder Parent Report for Outcome Monitoring: A Preliminary Report of Development and Clinical Utility. J Dev Behav Pediatr. 2021 May 01; 42(4):272-282. View Abstract
  26. EEG-IP: an international infant EEG data integration platform for the study of risk and resilience in autism and related conditions. Mol Med. 2020 05 07; 26(1):40. View Abstract
  27. Day-to-Day Test-Retest Reliability of EEG Profiles in Children With Autism Spectrum Disorder and Typical Development. Front Integr Neurosci. 2020; 14:21. View Abstract
  28. The Autism Biomarkers Consortium for Clinical Trials (ABC-CT): Scientific Context, Study Design, and Progress Toward Biomarker Qualification. Front Integr Neurosci. 2020; 14:16. View Abstract
  29. Use of longitudinal EEG measures in estimating language development in infants with and without familial risk for autism spectrum disorder. Neurobiol Lang (Camb). 2020; 1(1):33-53. View Abstract
  30. Biomarker Acquisition and Quality Control for Multisite Studies: The Autism Biomarkers Consortium for Clinical Trials. Front Integr Neurosci. 2020; 13(71). View Abstract
  31. Biomarker Acquisition and Quality Control for Multi-Site Studies: The Autism Biomarkers Consortium for Clinical Trials. Front Integr Neurosci. 2019; 13:71. View Abstract
  32. Longitudinal EEG power in the first postnatal year differentiates autism outcomes. Nat Commun. 2019 09 13; 10(1):4188. View Abstract
  33. Electroencephalographic spectral power as a marker of cortical function and disease severity in girls with Rett syndrome. J Neurodev Disord. 2019 07 31; 11(1):15. View Abstract
  34. Reduced frontal gamma power at 24 months is associated with better expressive language in toddlers at risk for autism. Autism Res. 2019 08; 12(8):1211-1224. View Abstract
  35. Early motor abilities in infants at heightened versus low risk for ASD: A Baby Siblings Research Consortium (BSRC) study. J Abnorm Psychol. 2019 Jan; 128(1):69-80. View Abstract
  36. Discovering translational biomarkers in neurodevelopmental disorders. Nat Rev Drug Discov. 2018 Dec 20. View Abstract
  37. BEAPP: The Batch Electroencephalography Automated Processing Platform. Front Neurosci. 2018; 12:513. View Abstract
  38. The Harvard Automated Processing Pipeline for Electroencephalography (HAPPE): Standardized Processing Software for Developmental and High-Artifact Data. Front Neurosci. 2018; 12:97. View Abstract
  39. EEG power at 3 months in infants at high familial risk for autism. J Neurodev Disord. 2017 Sep 13; 9(1):34. View Abstract
  40. Inhibition-Based Biomarkers for Autism Spectrum Disorder. Neurotherapeutics. 2015 Jul; 12(3):546-52. View Abstract
  41. Autism associated with early institutionalization, high intelligence, and naturalistic behavior therapy in a 7-year-old boy. J Dev Behav Pediatr. 2015 Jan; 36(1):53-5. View Abstract
  42. Social communication difficulties and autism in previously institutionalized children. J Am Acad Child Adolesc Psychiatry. 2015 Feb; 54(2):108-15.e1. View Abstract
  43. Motor outcomes in children exposed to early psychosocial deprivation. J Pediatr. 2014 Jan; 164(1):123-129.e1. View Abstract
  44. Clinical use of ictal SPECT in secondarily generalized tonic-clonic seizures. Brain. 2009 Aug; 132(Pt 8):2102-13. View Abstract
  45. Cortical and subcortical networks in human secondarily generalized tonic-clonic seizures. Brain. 2009 Apr; 132(Pt 4):999-1012. View Abstract
  46. Early treatment suppresses the development of spike-wave epilepsy in a rat model. Epilepsia. 2008 Mar; 49(3):400-9. View Abstract
  47. Shedding of tumor necrosis factor type 1 receptor after experimental spinal cord injury. J Neurotrauma. 2005 Aug; 22(8):919-28. View Abstract
  48. msJAMA. Genomics in medicine and public health: role of cost-effectiveness analysis. JAMA. 2001 Oct 03; 286(13):1637-8. View Abstract

Contact April Levin

Print Profile